Cochrane Evidence Synthesis and Methods ►

TNF-alpha inhibitors for psoriatic arthritis

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

The aim of this review is to assess the efficacy and safety of the TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab and onercept) in patients with PsA when compared with placebo or current standard treatment.

This review will address four core questions.

1. What is the clinical efficacy of TNF-alpha inhibitors for the treatment of PsA in terms of:

2. What are the risks (frequency and severity of adverse events) associated with use of TNF-alpha inhibitors in these patients?

This is a protocol.

Health topics:

Rheumatology > Spondylo-arthropathy

Published:

9 November 2020

Authors:

Golicki D, Macioch T, Niewada M, Jakubczyk M, Tlustochowicz M, Owczarek W, Tlustochowicz W

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Golicki D, Macioch T, Niewada M, Jakubczyk M, Tlustochowicz M, Owczarek W, Tlustochowicz W. TNF-alpha inhibitors for psoriatic arthritis (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007940. DOI: 10.1002/14651858.CD007940.